Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
29
SAVA Quote, Financials, Valuation and Earnings
Last price:
$2.21
Seasonality move
:
8.06%
Day range:
$2.19 - $2.33
52-week range:
$1.15 - $4.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.69x
P/B ratio:
1.37x
Volume:
626.8K
Avg. volume:
769.3K
1-year change:
-3.33%
Market cap:
$112.1M
Revenue:
--
EPS (TTM):
-$2.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
-- | -$0.68 | -- | -36% | $8.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835M | $0.56 | 4.63% | 9.11% | $88.39 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 31.89% | 267.32% | $14.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$0.32 | -100% | -3.03% | $4.00 |
|
YCBD
cbdMD, Inc.
|
$4.9M | -- | 11.43% | -- | $2.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
$2.32 | $8.00 | $112.1M | -- | $0.00 | 0% | 2.69x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$59.74 | $88.39 | $11.5B | 33.53x | $0.00 | 0% | 3.58x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.36 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.02x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.43 | $0.85 | $37.4M | 5.05x | $4.00 | 0% | 1.10x |
|
SPRO
Spero Therapeutics, Inc.
|
$2.19 | $4.00 | $123.4M | 10.75x | $0.00 | 0% | 4.15x |
|
YCBD
cbdMD, Inc.
|
$0.81 | $2.00 | $8.5M | -- | $0.00 | 0% | 0.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
-- | 4.470 | -- | 2.21x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.788 | 5.63% | 3.25x |
|
FOLD
Amicus Therapeutics, Inc.
|
61.73% | -0.359 | 9.99% | 1.72x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -1.682 | 8.08% | 1.85x |
|
SPRO
Spero Therapeutics, Inc.
|
11.23% | 14.109 | 3.17% | 3.63x |
|
YCBD
cbdMD, Inc.
|
6.18% | 0.621 | 4.36% | 1.84x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
-$200K | -$11.9M | -86.98% | -86.98% | -- | -$6.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
FOLD
Amicus Therapeutics, Inc.
|
$156.8M | $15.9M | -4.09% | -12.36% | 8.61% | $16M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$9.7M | -97.58% | -107.04% | -319% | $17.4M |
|
YCBD
cbdMD, Inc.
|
$2.8M | -$286.3K | -39.12% | -47.18% | -5.71% | -$977.3K |
Cassava Sciences, Inc. vs. Competitors
-
Which has Higher Returns SAVA or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -5.2%. Cassava Sciences, Inc.'s return on equity of -86.98% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About SAVA or BMRN?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 244.83%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.39 which suggests that it could grow by 47.96%. Given that Cassava Sciences, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Cassava Sciences, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is SAVA or BMRN More Risky?
Cassava Sciences, Inc. has a beta of -0.848, which suggesting that the stock is 184.779% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.248, suggesting its less volatile than the S&P 500 by 75.229%.
-
Which is a Better Dividend Stock SAVA or BMRN?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or BMRN?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. Cassava Sciences, Inc.'s net income of -$10.8M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 33.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 3.58x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M BMRNBioMarin Pharmaceutical, Inc.3.58x 33.53x $895M -$46.6M
-
Which has Higher Returns SAVA or FOLD?
Amicus Therapeutics, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of 0.91%. Cassava Sciences, Inc.'s return on equity of -86.98% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M FOLDAmicus Therapeutics, Inc.84.64% $0.01 $716.6M -
What do Analysts Say About SAVA or FOLD?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 244.83%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 0.98%. Given that Cassava Sciences, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Cassava Sciences, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is SAVA or FOLD More Risky?
Cassava Sciences, Inc. has a beta of -0.848, which suggesting that the stock is 184.779% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.430, suggesting its less volatile than the S&P 500 by 56.973%.
-
Which is a Better Dividend Stock SAVA or FOLD?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or FOLD?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Cassava Sciences, Inc.'s net income of -$10.8M is lower than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 7.02x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M FOLDAmicus Therapeutics, Inc.7.02x -- $185.2M $1.7M
-
Which has Higher Returns SAVA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -255.85%. Cassava Sciences, Inc.'s return on equity of -86.98% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About SAVA or NBY?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 244.83%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could grow by 197.2%. Given that Cassava Sciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cassava Sciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is SAVA or NBY More Risky?
Cassava Sciences, Inc. has a beta of -0.848, which suggesting that the stock is 184.779% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.246, suggesting its less volatile than the S&P 500 by 75.426%.
-
Which is a Better Dividend Stock SAVA or NBY?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $4.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or NBY?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cassava Sciences, Inc.'s net income of -$10.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 5.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 1.10x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M NBYNovaBay Pharmaceuticals, Inc.1.10x 5.05x $521K -$1.3M
-
Which has Higher Returns SAVA or SPRO?
Spero Therapeutics, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -242.19%. Cassava Sciences, Inc.'s return on equity of -86.98% beat Spero Therapeutics, Inc.'s return on equity of -107.04%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M -
What do Analysts Say About SAVA or SPRO?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 244.83%. On the other hand Spero Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 82.65%. Given that Cassava Sciences, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe Cassava Sciences, Inc. is more attractive than Spero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 SPROSpero Therapeutics, Inc.0 1 0 -
Is SAVA or SPRO More Risky?
Cassava Sciences, Inc. has a beta of -0.848, which suggesting that the stock is 184.779% less volatile than S&P 500. In comparison Spero Therapeutics, Inc. has a beta of 1.454, suggesting its more volatile than the S&P 500 by 45.384%.
-
Which is a Better Dividend Stock SAVA or SPRO?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. Spero Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or SPRO?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than Spero Therapeutics, Inc. quarterly revenues of $3M. Cassava Sciences, Inc.'s net income of -$10.8M is lower than Spero Therapeutics, Inc.'s net income of -$7.4M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while Spero Therapeutics, Inc.'s PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 4.15x for Spero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M SPROSpero Therapeutics, Inc.4.15x 10.75x $3M -$7.4M
-
Which has Higher Returns SAVA or YCBD?
cbdMD, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -5.64%. Cassava Sciences, Inc.'s return on equity of -86.98% beat cbdMD, Inc.'s return on equity of -47.18%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M YCBDcbdMD, Inc.54.93% -$0.04 $9.6M -
What do Analysts Say About SAVA or YCBD?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 244.83%. On the other hand cbdMD, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 146.31%. Given that Cassava Sciences, Inc. has higher upside potential than cbdMD, Inc., analysts believe Cassava Sciences, Inc. is more attractive than cbdMD, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 YCBDcbdMD, Inc.0 0 0 -
Is SAVA or YCBD More Risky?
Cassava Sciences, Inc. has a beta of -0.848, which suggesting that the stock is 184.779% less volatile than S&P 500. In comparison cbdMD, Inc. has a beta of 2.127, suggesting its more volatile than the S&P 500 by 112.722%.
-
Which is a Better Dividend Stock SAVA or YCBD?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. cbdMD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. cbdMD, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or YCBD?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than cbdMD, Inc. quarterly revenues of $5M. Cassava Sciences, Inc.'s net income of -$10.8M is lower than cbdMD, Inc.'s net income of -$283.1K. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while cbdMD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 0.26x for cbdMD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M YCBDcbdMD, Inc.0.26x -- $5M -$283.1K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 12.44% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 5.95% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 0.41% over the past day.
